For early prevention or inhibition of postmenopausal and age-related bone loss, nutritional interventions might be a first choice. For some vitamins and minerals an important role in bone metabolism is known or suggested. Calcium and vitamin D support bone mineral density and are basic components in most preventive strategies. Magnesium is involved in a number of activities supporting bone strength, preservation, and remodeling. Fluorine and strontium have bone-forming effects. However, high amounts of both elements may reduce bone strength. Boron is especially effective in case of vitamin D, magnesium, and potassium deficiency. Vitamin K is essential for the activation of osteocalcin. Vitamin C is an important stimulus for osteoblast-derived proteins. Increasing the recommended amounts (US RDA 1989), adequate intakes (US DRI 1997), or assumed normal intakes of mentioned food components may lead to a considerable reduction or even prevention of bone loss, especially in late postmenopausal women and the elderly.
I. INTRODUCTION
Bone loss at an older age (>50 years) will sooner or later lead to osteoporosis and fractures in millions of people associated with a decrease in general well-being and with high costs for health care, especially in the case of hip fractures. 1 Bone mass, architecture, and composition are largely under genetic control and strongly influenced by mechanical stress in an early stage of life. However, to achieve one's genetic potential, adequate nutrition during growth and maintenance is necessary for optimum skeletal development and health. 2 A first step in the prevention of osteoporosis is a high bone mass during puberty and adolescence. Between peak bone mass and the age of about 50, bone mass has to be preserved by a healthy life style and adequate nutrition. After that period, strategies to preserve bone strength should start as soon as possible. 3 Although architecture plays an important role in bone strength, a valid and noninvasive predictor of fracture risk at an older age is bone mineral density (BMD). 4 At an older age, bone mass decreases as a result of aging (type 2 or senile osteoporosis), decreased synthesis of gonadal hormones (type 1 or postmenopausal osteoporosis), and often by malnutrition. Only during the early postmenopausal phase (less than 5 years following menopause), nutritional intervention seems to be less effective. 1 Vitamin D, and especially calcium, return regularly in preventive strategies. However, other food ingredients also play important roles, assisting calcium and vitamin D or just by completing nutrition. Copper, manganese, and zinc are cofactors for enzymes involved in bone metabolism. 5 Premenopausal higher intakes of zinc, magnesium, potassium, fiber, and vitamin C were associated with a higher BMD of the lumbar spine. Positive influences on BMD of the lumbar spine and femoral neck were seen in early adulthood because of adequate milk and fruit intakes. 6 Fluorine is known to stimulate bone formation. 1 Such a function has also been suggested for strontium. 7 The role boron plays in maintaining bone mineral density is less clear. 8 Silicon and aluminum are thought to increase the thickness of trabeculae, whereas aluminum also might increase connectivity of trabecular bone. 9 However, aluminum is also mentioned as an inhibitor of hydroxyapatite growth. 10 Vitamin K is known as a co-factor in the activation of a number of proteins involved in bone metabolism. 1 This article reviews the current knowledge about the role of calcium, vitamin D, magnesium, strontium, fluorine, boron, vitamin K, and vitamin C on bone metabolism in postmenopausal women.
II. CALCIUM
To secure vital activities, serum calcium concentration is maintained within narrow limits (range 2.1 to 2.6 mmol/L), a process controlled by the hormones calcitriol (1,25(OH) 2 D 3 ), parathyroid hormone (PTH), and to a lesser extent calcitonin. 11 It has been suggested that the calcium intake of postmenopausal women should be at least 1500 mg per day, 12 which is higher than the U.S. adequate daily intake of 1200 mg. 13 Important dietary calcium sources are dairy products. 14 Dark leafy green vegetables are also rich in calcium but often with a lower bioavailability except for Brassica vegetables such as broccoli. 15 Less well-known calcium sources are fatty fish (the small fish bones included), nuts, and subtropical fruits. 16 To achieve high calcium intakes, calcium supplements may be necessary that differ in purity, percentage of elemental calcium, and solubility. In subjects without health problems, calcium intakes up to 2,500 mg are safe. 13 High intakes of calcium are not related to kidney stone formation and might even prevent this by binding dietary oxalate in the intestine. 17, 18 However, increased calcium intakes, already in amounts of 300 mg, limit the absorption of dietary iron (including heme iron). 18 Although this will not harm bone metabolism directly, anemia and tiredness 19 will negatively affect physical activity, and as a consequence may stimulate bone resorption. Inhibition of zinc absorption can be overcome by zinc supplementation, 20 whereas a reduced magnesium absorption might be compensated by reduced urinary losses. 21 
A. Absorption and Losses of Calcium
Reported mean absorption percentages of calcium range from 24 to 35%. 11, 13, 22 Passive calcium absorption, which is determined by amount of calcium consumed, is of major importance for the elderly (65 years and older). Their active transport of calcium may be less efficient due to reduced serum calcitriol concentrations and a reduced gastrointestinal sensitivity to calcitriol. 1 Small differences in intestinal calcium absorbability seem to have a low impact on calcium balance in healthy middle-aged women. Differences in urinary calcium excretion are of major importance. 1, 23 Urinary calcium losses increase after the menopause apparently for a period of 15 to 20 years. 11 It has been hypothesized 24 that the rise in bone resorption is secondary to a decreased reabsorption of renal calcium as a result of a lowered sensitivity of the kidneys for PTH because of estrogen deficiency.
B. Effects of Calcium Supplementation in Elderly and Postmenopausal Women
Increases in trabecular BMD after calcium supplementation, which result from closure of remodeling spaces (the so-called remodeling transient), can be considered as a short-term effect (6 to 12 months), 25, 26 but this effect may remain when supplementation is continued. 27, 28 Calcium supplementation reduces bone turnover, possibly by suppressing PTH secretion, 1 which takes place especially during the first hours after intake. 29 Vitamin D is also known to inhibit bone resorption by reducing the circulating amounts of PTH. 30 Senile hyperparathyroidism was treated with a daily dosage of about 1000 mg of calcium in combination with 400 to 800 IU of vitamin D. [31] [32] [33] Menopause-related bone loss already starts during the years immediately preceding menopause. This loss of bone (about 2% per year) was reduced substantially by supplementation with 1000 or 2000 mg calcium. 34 During the first 5 to 10 years after menopause bone comes into a new steady state at about a 15% lower bone mass. 35 This estrogen deficiency-related bone loss cannot be prevented by calcium supplementation (500 to 1200 mg) with 36 or without vitamin D. Only a moderate inhibition was reported in particular for compact bone. 25, 37 No effect in early postmenopausal women probably can be explained by already reduced levels of PTH, and calcitriol, as a consequence, because serum calcium levels are sufficient due to the increased bone resorption. 38, 39 This also might explain the reported prevention of bone loss from the lumbar spine in young women with estrogen deficiency by PTH treatment (increased calcitriol synthesis and calcium absorption). 40 If bone resorption is inhibited (e.g., by hormone replacement therapy) calcium supplementation becomes more effective during this early postmenopausal period. 41 The greatest benefits of calcium supplementation are reported from studies in elderly (>70 years of age) 32, 42 and late postmenopausal women (>9 years postmenopausal) 27, 37, [43] [44] [45] who have moderate losses of trabecular and cortical bone of about 1% per year. In a study with Swedish postmenopausal women, 46 a positive relation with BMD was found at estimated calcium intakes above 1400 mg per day. Heaney et al. 47 showed that increased milk consumption (about 700 mg additional calcium per day) reduced bone turnover within 12 weeks. Total daily calcium consumption was about 1400 mg. The milk, however, also supplied about 200 IU vitamin D. An additional effect of vitamin D on calcium supplementation is likely, especially in the case of a marginal vitamin D status. Other studies 27, 43, [48] [49] [50] indicate that supplementation with 800 to 1250 mg of calcium per day is beneficial for BMD of the lumbar spine, especially during the early phase of supplementation ( Figure 1 ). Effects on BMD of the femoral neck and total proximal femur are contradictory but might be positive in the longterm. Lower amounts of supplemented calcium (500 mg per day) are not or less effective, especially in combination with low dietary calcium intakes. 37, [51] [52] [53] [54] This suggests that the total daily calcium intake should be ≥ 1500 mg for a positive influence on bone. In Northern Europe, however, high calcium intakes go hand in hand with a high incidence of osteoporosis. Recently, it has been suggested that this is not related to the high calcium intake but probably to excessive daily intakes (>1.5 mg) of retinol (not of pro-vitamin A carotenoids). 55 It has to be considered, however, that comparison of the studies referred to is difficult because the contribution of dietary calcium intake differed from 400 to about 1000 mg per day. Besides that, different calcium preparations were used and supplements were sometimes given in divided doses during the day, which increases daily absorption.
The above-mentioned studies indicate that a high total daily calcium intake (≥1500 mg) seems to be important for a positive effect on bone. At the same time, however, attention has to be paid to other nutrients, such as vitamin A, which may reduce the calcium effect.
III. VITAMIN D
Vitamin D deficiency is associated with rickets, osteoporosis, muscle weakness, and decreased immune function. 56, 57 Based on the serum level of calcidiol (25(OH)D 3 ), vitamin D status has been defined as lowered (<100 nmol/L), insufficient (25 to 50 nmol/L), or deficient (<25 nmol/L). 58 For healthy subjects there is no evidence of adverse effects with serum calcidiol concentrations <140 nmol/L. The highest 'natural' level obtained from sunshine was found to be 225 nmol/L. 59 Calcitriol (1,25(OH) 2 D 3 ) is the most active metabolite of vitamin D, and specific receptors are found in many tissues. 56 The most well-known function is the support of active intestinal calcium absorption. Fatty fish, fish-liver oils (herring liver oil in particular), and liver are rich sources of vitamin D 3 . Products such as milk, yogurt, margarine, and breakfast cereals are important contributors if they are fortified with vitamin D. Vitamin D 2 (of vegetable origin) plays a minor role in the overall vitamin D intake. 1,60 U.S. Adequate intakes 13 for ages 51 to 70 and over 70 years are 400 and 600 IU per day, respectively. However, higher dosages (800 to 1000 IU/day) might be preferable for the older age group. 59, 61 To prevent adverse effects in the healthy adult population, the dietary intake of vitamin D should probably not exceed 2400 IU per day. 61 Extreme intakes of vitamin D (>10,000 IU per day) resulted in serum calcidiol levels with considerable biological activity, which may lead to extraosseous calcifications. 62 FIGURE 1. Effects of calcium supplementation without additional vitamin D on BMD of the lumbar spine. Changes are presented as a percentage from baseline after 12, 24, 36, or 48 months of intervention. Information is presented about the calcium source, amount of supplemented elemental calcium, the amount of dietary calcium, and the age of participants.
A. Absorption and Synthesis of Vitamin D and Its Metabolites
Vitamin D is absorbed in the small intestine in association with dietary fat or synthesized in the skin after exposure to UV light. 56 Skin-derived vitamin D 3 may account for about 50% of circulating vitamin D 63 and 80 to 90% of the body stores. 60, 62 Latitude determines when an adequate synthesis of vitamin D can take place. Above and below latitudes of approximately 40°N and 40°S, respectively, synthesis of vitamin D 3 in the skin is absent during most of the winter months. 13, 64 Especially in the liver, but also in many other tissues, vitamin D can be converted into calcidiol. This hydroxylation is catalyzed by 25-α-hydroxylase. 65 Although calcidiol synthesis depends primarily on the amount of circulating vitamin D, 1 its level is maintained within the range of about 75 to 220 nmol/L across vitamin D supplies from 800 to 10,000 or 20,000 IU per day. 59 The synthesis of calcidiol is more effective from vitamin D 3 than from D 2 , which is possibly because of a higher affinity of vitamin D 3 for vitamin D binding protein (DBP). 66 Circulating calcidiol concentrations are found to be higher in men than in women, 67 higher in white women than in black women, 68 and seem to be inversely correlated with body mass index 67 and age. 60 In the kidney, calcidiol can be converted into calcitriol by 1α-hydroxylase. Minor amounts of calcitriol may be produced in other tissues such as bone cells, monocytes, and macrophages. In circulation, the major part of calcitriol is bound to vitamin D binding protein. Only about 0.4% appears free or unbound in serum and is hormonally active. The synthesis of calcitriol is stimulated by PTH and phosphate and is less influenced by the amount of circulating calcidiol. 1 Calcitriol and increased serum calcium lower serum PTH levels. 56 Calcitriol also inhibits its own synthesis in the kidney by binding to the vitamin D receptor (VDR) that stimulates the enzyme 24hydroxylase. This enzyme mediates the initial step in a cascade of oxidation's that ultimately results in calcitroic acid. 69 The major route of excretion of vitamin D and its metabolites is in the feces. 56
B. Vitamin D Receptor (VDR)
Non-genomic actions of calcitriol involve the opening of voltage-sensitive calcium channels and the activation of protein kinases, through which changes occur in intracellular calcium, phospholipid metabolism and phosphate transport, alkaline phosphatase and adenylate cyclase activities, 1 and membrane fluidity. 56 Some of these rapid nongenomic actions of calcitriol might be mediated by a membrane-bound VDR. 70 The genomic VDR-mediated mechanism influences gene transcription. 62 The expression of VDR can be up-and down-regulated by hormones and growth factors. Subtle changes in the number or genotype of VDR are expected to play a major role in changes of bone metabolism. An age-related decline in intestinal VDR creates a relative calcitriol-resistant state and impairs active calcium absorption. 1 It has been suggested that polymorphism of the VDR gene may account for a substantial proportion (as much as 20% 71 ) of the heritable component of BMD. 72 However, this hypothesis remains controversial, is possibly more pronounced in younger subjects, and might be true only in case of low calcium intakes. 73 In Asian ethnic groups with a traditionally low calcium intake, VDR genotypes associated with a low BMD have a lower frequency compared with the Western populations, which points to a genetic selection. Aside from BMD, VDR polymorphism's might be linked to cellular proliferation, osteophyte formation, prostate cancer, hyperparathyroidism, and perhaps diabetes. 74
C. Classic Actions of Vitamin D
The responses to calcitriol are tissue specific and depend on the state of cellular differentiation and concentration of calcitriol. This implies that effects may be opposite to each other, as has been reported for calcitonin and type 1 collagen. 1, 75 In Table 1 a number of calcitriol-regulated proteins are listed. The active uptake of calcium as well as the Na + -dependent uptake of phosphate is controlled by calcitriol. 1 This control may be as high as 60% in case of low calcium intakes or as low as 20% at calcium intakes of about 1500 mg. 64 Estrogens stimulate active calcium absorption by upregulation of gut VDR, 62 and by increasing serum levels of DBP. 1 In bone, the principal target cells for calcitriol are believed to be the osteoblasts, 76 with effects being dependent on the stage of cell differentiation and calcitriol concentration. In rat and osteosarcoma cell cultures, it was found that genes of osteocalcin, alkaline phosphatase, and collagen are down-regulated in proliferating immature osteoblasts but up-regulated in mature osteoblasts. 1, 60 With regard to osteoclasts, calcitriol stimulates the retraction of nodule-associated osteoblasts to allow for osteoclast interaction, stimulates the differentiation of promonocytes into osteoclasts, and activates the synthesis of β 3 protein, which is part of the osteoclast surface marker α v β 3 . Binding of this marker to the bone matrix protein osteopontin finally stimulates bone resorption. 1 Some of the bone resorption stimulating effects of calcitriol may be through the upregulation of epidermal growth factor (EGF) receptors. 77 It is thought that the osteoclast-mediated effects are especially stimulated in case, of high, pharmacological doses vitamin D for long periods. 75, 78 In skeletal muscle tissue, calcitriol controls muscle contraction through a direct effect on calcium transport and may reduce instability and falls in the elderly. 56, 79 In the kidney, calcitriol regulates the 1α-and 24hydroxylases and the synthesis of calbindin D28k, a protein mediating the active calcium reabsorption. 1 With age, when renal mass and function falls, including the capacity to synthesize calcitriol, 2 a mild secondary hyperparathyroidism may develop to stimulate 1α-hydroxylase ( Figure 2 ). 1, 78 Vitamin D deficiency, a decreased number of VDR in the parathyroid gland and estrogen deficiency can also cause hyperparathyroidism. 1, 11 Hyperparathyroidism not only stimulates calcitriol synthesis and, hence, intestinal calcium absorption, but also bone turnover. 38
D. Effects of Vitamin D Supplementation
Supplementation can take place by giving either vitamin D or one of its metabolites. 75 Major effects of vitamin D treatment are a lowering of serum PTH levels and an increase in intestinal calcium absorption. 30, 80 Therefore, in early postmenopausal women vitamin D might be less effective because PTH levels are said to be already reduced because of adequate serum calcium levels. 39 However, these women may develop an increased sensitivity to normal serum levels of PTH that stimulates bone turnover. Small or no effects were seen with 300 or 400 IU of vitamin D per day on BMD or calcitriol synthesis in early postmenopausal women with a high calcium intake. 81, 82 The treatment of early postmenopausal Japanese women 83 with an oral dose of 0.75 µg of 1-α-hydroxyvitamin D 3 decreased serum PTH levels and bone resorption, and slightly but signifi-cantly increased BMD of the lumbar spine. This study supports the idea that vitamin D treatment in early postmenopausal women is most effective when synthesis of calcitriol is not or less dependent on serum PTH levels. 84 In the elderly, additional dietary vitamin D (up to 800 IU per day) possibly prevents an important number of fractures, particular in those on a marginal calcium and vitamin D intake. 85, 86 In Finnish elderly with a suggested adequate intake of calcium, a single injection of 150,000 to 300,000 IU vitamin D significantly reduced all fractures. 87 A reduced fracture incidence was also reported by Chevalley et al. 42 after a single injection of 300,000 IU vitamin D in combination with 800 mg calcium per day. Daily supplementation with 700 IU 88 and 800 IU 32 vitamin D, in combination with 500 and 1200 mg calcium, respectively, showed the same effect. Postmenopausal women with osteoporosis formed less new vertebral fractures after 2 years of intervention with daily intakes of 1000 mg calcium and 800 IU vitamin D 2 . These women, however, still lost bone from the femoral neck. 89 Postmenopausal women with a low daily calcium intake of 950 mg, including 500 mg from supplementation, combined with 700 IU vitamin D only increased BMD of the lumbar spine and the femoral neck during the first year of the study. After the second year, BMDs were below baseline values. 90 The results of a Dutch study 86 were not in line with the findings of a previously mentioned French study. 32 The Dutch participants, who did not show a reduction in hip fractures, differed by being relative healthy and by already having a lower incidence of hip fractures. Furthermore, they received no additional calcium, had a lower total daily calcium intake and a lower vitamin D supplementation (400 IU vs. 800 IU) compared with the French. None of these factors support a reduction in fracture incidence. In addition, the dosage of 400 IU of vitamin D was reported to be ineffective in postmenopausal osteoporosis. 75 In combination with estrogen therapy, 300 IU of vitamin D 3 per day had an additional positive effect on femoral neck BMD in osteoporotic women (7.1 years postmenopausal, 750 mg calcium per day). 84 The above-mentioned studies indicate that an effect of vitamin D on BMD is likely, especially in case of a marginal vitamin D status. Furthermore, for a positive effect on bone, vitamin D supplementation should be combined with an adequate total daily calcium intake.
IV. MAGNESIUM
Magnesium is the fourth most abundant element in the body, about 25 g in total. 19 Normally, 34% of total body magnesium is intracellular, 1% is extracellular, and about 65% is located in bone. 91, 92 Complexed with ATP, magnesium takes part in many enzyme reactions such as cAMP formation, phosphorylations, and in protein and nucleic acid synthesis. 19 Magnesium intake is said to be marginal in the entire population, 93 but deficiency is seldomly seen. For healthy adult men and women, recommended intakes 13 are 420 and 320 mg per day, respectively. Magnesium is present in most foods, in particular those of vegetable origin containing chlorophyll. 19 High concentrations are found in whole seeds. Relatively poor sources are fish, meat, milk, and commonly eaten fruits, with the exception of bananas. 94 The tolerable upper limit for magnesium from nonfood sources (i.e., additional magnesium) for adults is 350 mg. The first effect of excessive magnesium intake is diarrhea. 13
A. Intestinal Absorption and the Role of Magnesium in Bone Metabolism
The intestinal absorption, active as well as passive, varies from 25 to 75% on high-and lowmagnesium diets, respectively. 19 With increasing age, magnesium absorption decreases. In people older than 70 years of age it is about 70% of what is was at the age of 30. This may lead to disturbances in bone, kidney, and hormone metabolism. Aside from a reduced absorption, magnesium may also be lost as a result of urinary leakage (organ function and use of diuretics), diseases, and/or their treatments. 93 Five functions are suggested for magnesium in bone metabolism, affecting remodeling, strength, and preservation. [95] [96] [97] First, magnesium, which appears to be located on the crystalline surface of bone, destabilizes hydroxyapatite crystals, and prevents hydroxyapatite crystal formation. This limitation of hydroxyapatite crystal size increases bone strength. 5, 98, 99 Secondly, magnesium is necessary to maintain the pH of extracellular fluid (ECF) somewhat higher than the pH of blood. In this way a barrier is formed to prevent calcium leakage from bone because of a low blood pH. Patients with osteoporosis showed a decreased ECF pH. 95 Uncontrolled hydrogen ion excretion (via a Na + -H + exchange carriers) by osteoclasts, or insufficiently working potassium pumps of osteocytes can disturb this ECF barrier. 100, 101 A higher pH of ECF also might inhibit the resorption activ-ity of osteoclasts. 102 Third, magnesium stimulates calcitonin, which inhibits osteoclasts. 91 Furthermore, magnesium deficiency, intracellular depletion in particular, was found to correlate with low-serum PTH levels that may result in symptomatic hypocalcemia. 91, 92, 103 Under these conditions, hydroxyapatite crystals may grow larger, 98 active bone resorption will be impaired, and calcitriol synthesis may be decreased. The 1αhydroxylation of calcidiol is a magnesium-dependent and PTH stimulated reaction. 104 Finally, in vitro proliferation of osteoblast-like cells was directly related to magnesium concentrations in the medium. 92 Hypomagnesemia in rats resulted in a decreased trabecular bone volume, decreased osteocalcin levels, and a decreased mineral content of the newly formed metaphysis. 99
B. Effects of Magnesium Supplementation
Higher intakes of dietary magnesium were associated with a higher BMD in elderly men and women in a community-based study, 105 and in Japanese elderly living in Hawaii. 106 In a crosssectional study with 62 healthy women (45 to 55 years of age) higher intakes of magnesium, and also of potassium and alcohol, were associated with higher total bone mass. 107 These higher intakes of magnesium and potassium were a result of higher fruit and vegetable consumption. Mean magnesium and calcium intakes were 326 and 1101 mg per day, respectively. In two studies with postmenopausal women, 108,109 however, no associations were found between daily intakes of about 250 mg of dietary magnesium and BMD. Two more recently published studies with postmenopausal women suggest an effect of magnesium on BMD after 2 years of supplementation but with higher daily intakes of magnesium. 92, 110 In five patients with gluten-sensitive enteropathy, 92 BMD of the femoral neck and total proximal femur increased significantly after an intake of about 500 mg of magnesium per day for 2 years. The increase in lumbar spine BMD was not significant. In 14 women it was shown that serum PTH, possibly involved in the effect on BMD, rose only in magnesium-depleted subjects and not in subjects with an adequate magnesium status. Low-serum PTH may result in hypocalcemia and, as a consequence, may negatively affect bone metabolism. Magnesium status was assessed by the determination of serum magnesium, red blood cell and lymphocyte free magnesium, and total lymphocyte magnesium. Unfortunately, this study was not placebo controlled. In an open, controlled Israelian study with postmenopausal women (n = 31), 110 BMD of the ultra-distal radius of the forearm was significantly increased (1 to 8%) after 2 years of supplementation with 250 mg of magnesium per day. Total daily magnesium intake was about 500 mg. In untreated controls, mean bone density significantly decreased. High intakes of magnesium in combination with low dietary calcium, however, were found to be a risk factor for hip fracture. The reason for this is not clear, but an impairment of calcium absorption and stimulation of calcium excretion has been proposed. 111 Despite the small number of studies performed, the small number of participants involved, and questionable study designs, a positive effect of magnesium on bone health may be suggested. Magnesium supplementation should be accompanied by an adequate supply of calcium.
V. STRONTIUM
Strontium is the most abundant trace element in sea water (up to 8 mg/L), and as a consequence levels in seafood may be as high as 25 mg/kg. 112 The body store is about 350 mg, of which 99% is present in bones. 19 The radioactive as well as the stable form of strontium have been found in cow's milk. The potentially dangerous radioactive strontium concentrations 113 reflect environmental contamination (e.g., above-ground nuclear tests). 114 Stable strontium concentrations in full cream milk have been found to range from 180 to 2800 µg/L. 113 Other dietary sources are meat, poultry, wheat bran and the peel of root vegetables. The content in drinking water varies from 20 to 60 µg/L, but higher values have been reported. Daily intakes are estimated to be about 1 to 3 mg. 19, 115 Although the lethal doses for 50% of tested mice (LD50) for stable strontium chloride was about 5000 mg/kg of body weight, 116 much lower amounts (about 76 mg per day) were found to have deleterious effects on bone in rats. 117
A. Absorption and Action in Bone
The intestinal absorption of strontium and its uptake in bone mineral is discriminated in favor of calcium. [118] [119] [120] In animal studies, this discrimination develops with age. 118 In adults, only 20 to 40% of the ingested strontium passes through the intestinal wall. About 99% of the absorbed amount is stored in bone mineral. 119 Clearance of strontium seems to be rapid. 121 In animal models, positive effects on trabecular and cortical bone have been found, 122 and a positive correlation was found between bone strength and strontium content. 123 Strontium easily exchanges calcium on the surface (i.e., adhesion) of hydroxyapatite crystals in old and new bone, and into (i.e., substitution) the crystals of new bone. 120, 121 The physiological effects of adhesion or substitution, however, are different. In vitro, adhesion (up to about 25% of calcium) inhibited the dissolution of calcium hydroxyapatite and increased bending strength. In contrast, substitution (strontium substituting 10% of calcium) resulted in a faster dissolution in water, a reduced bending strength, 123 and slowed down hydroxyapatite deposition. 124 High intakes of strontium may also block the biosynthesis of calcidiol into calcitriol and hence decrease the active intestinal calcium absorption. 112 In monkeys, a short-term treatment with a high dosage of strontium (up to 128 mg/kg/day) during 13 weeks did not cause disturbances in bone apposition and calcification. 121 In animals and in vitro a positive, direct influence of strontium on osteoblastic cells was found. 7, 125, 126 A stimulated bone formation may cause a transitory slight decrease in serum calcium levels. 117, 127 In culture and in young growing animals, strontium increased levels of complexed acidic phospholipids (CPLX) that appear to play a role in initiating bone mineralization. 101, 120 In vitro, however, the strontium increased CPLX abolished calcium incorporation. This may be a result of decreased matrix vesicle degradation that is necessary for mineralization. 112 Growing hydroxyapatite crystals, inside the matrix vesicles, finally disrupt the matrix vesicle wall. 128 High intakes of strontium may prevent this disruption through the inhibition of hydroxyapatite crystal growth. Strontium seems to increase non-collagenous proteins of which several prevent hydroxyapatite precipitation, 112 and/or because incorporation of strontium into the initial hydroxyapatite crystals impairs further proliferation. 120
B. Effects of Strontium Supplementation
In the 1950s, strontium lactate was already used to treat osteoporosis in daily doses representing 1700 mg of strontium for periods ranging from 3 months to 3 years. 129 Postmenopausal, osteoporotic women were supplemented for 2 years with about 340 mg of strontium per day (in the form of S12911) resulting in a in a significant increase in lumbar spine BMD and a reduced number of new vertebral fractures. 122 Although strontium may cause false-positive BMD increases, because it has a higher atomic number than calcium, 124 an increased BMD of the lumbar spine was also found after adjustment for bone strontium content in early postmenopausal women with a daily intake of 170 mg of strontium (S12911) and 500 mg of calcium for 2 years. The placebo group showed a decreased BMD. 130 In pain treatment, for example, caused by bone metastases and osteoporosis, not only radioactive strontium but also stable strontium has been shown to be successful. 117, 129, 131 In vitro studies, and animal studies, indicate that strontium might have an anabolic effect on bone. In human studies positive effects on BMD are reported. However, because high intakes of strontium may impair bending strength, vitamin D metabolism and bone mineralization, chronic intakes of low amounts might be preferred.
VI. FLUORINE
Fluorine is an essential trace element required for normal dental and skeletal development. 132 However, long-term consumption (>10 years) of relatively low amounts of fluorine per day (≥10 mg) may lead to skeletal fluorosis. The adequate daily intake for individuals 19 years and older is 3.8 mg and 3.1 mg per day for males and females, respectively, with a tolerable upper level of 10 mg per day. 13 About 99% of the body fluorine is found in bone and increases with age because of a long residence time. 56 At concentrations as high as 10,000 ppm, bone strength decreases by about 13% at recommended calcium intakes (1000 to 1200 mg per day) or by as much as 45% in the case of calcium deficiency. 132 The concentrations of fluorine in soil, water, and many foods vary due to soil fertilizers, pollution, and enrichment strategies. A rich source of fluorine is tea. 13 High intakes of tea have been associated with fluorosis. 133 In patients with renal deficiency, small doses equivalent to 3 to 10 mg per liter of drinking water may already impair mineralization. 134
A. Intestinal Absorption and Action on Bone
Fluorine is passively absorbed from the intestine, lungs, and skin. In the intestine, absorption ranges from 90% in water to 65 to 100% in food and fluoride preparations. 1, 132, 135 Absorption is negatively affected by low gastric acid secretion and concurrent administration of calcium 1 except for sodium mono-fluorphosphate. In air, hydrogen fluoride is the dominant form that is rapidly absorbed from the respiratory tract. 132, 135 In the body, fluorine stimulates the proliferation of preosteoblasts, 132 which increases the number of osteoblasts 136 without affecting bone resorption. A stimulation of osteoblastic activity leads to overfilling of resorption cavities, increasing trabeculae thickness and bone volume. 1 Vitamin D supplementation seems to be necessary to blunt the increase in osteoid thickness, stimulating a proper mineralization. There is no evidence that fluorine supplementation will lead to the formation of new trabeculae at an older age. 137 The action on preosteoblasts is mediated by one or more growth factors such as insulin-like growth factor I (IGF-I) and transforming growth factor-β (TGFβ). 1 It also has been suggested that, due to fluoride treatment, flat lining cells dedifferentiate into osteoblasts or become replaced by new osteoblasts, bypassing the normal sequence of remodeling. 137 Theoretically, active fasting serum fluorine levels, substantiated by increased BMD in fluoride-treated patients to stimulate osteoblasts ranges from 5 to 15 µmol/L. 1, 132 Such levels have been recorded at an intake of 26.4 mg of fluorine per day. 138 Proposed cellular mechanisms are based on the G protein (guanyl nucleotide-binding proteins) hypothesis and the tyrosine phosphatase hypothesis. 139 In the G protein hypothesis, fluorine activates a heterotrimeric G protein, probably by interaction with GDP to form a GTP-like molecule. Activation of GTP-binding proteins may stimulate protein kinase C, which subsequently leads to cell proliferation. 1, 79, 139 The tyrosine phosphatase hypothesis is based on inhibition of phosphotyrosyl protein phosphatase (PTPP) by fluorine ( Figure 3 ). 1 Due to the inhibition of PTPP, activation of a receptor tyrosine-kinase 140 by growth factor binding such as IGF-I or TGFβ leads to a cascade of phosphorylations, DNA synthesis, and finally to cell proliferation. Evidence for the PTPP route is the blocking of the mitogenic effect of fluorine by the phytoestrogen genistein found in soybean, which is a tyrosyl kinase inhibitor. 1 Extracellularly, the incorporation of fluorine (substituting hydroxyl ions) in bone, particularly in newly formed trabecular bone, results in the formation of fluoroapatite crystals, which are less soluble and larger than the hydroxyapatite crystals. 1, 141, 142 Larger crystals predict an increased compressive strength, but a reduced bending strength, which might explain a reported increase in crystal brittleness. 1
B. Effects of Fluoride Supplementation
Fluoride in dosages of 50 to 75 mg sodium fluoride (26.4 to 33.9 mg of fluorine) per day increased calcium balance, 100 bone mineralization, and in vitro collagen production. 141 Positive effects on BMD are especially seen in the axial skeleton and may last for as long as 6 years. 1 Other sites, for example, hip and forearm, might be positively or negatively affected depending on concentrations of fluorine and calcium. Calcium may become marginal as a result of increased bone formation. 1, 136, 138 Effects on fracture prevention are not clear. Treatment with about 40 mg of fluorine per day increased the rate of appendicular fractures and microfractures. 143 A fluoridation strategy of drinking water (1 ppm) in Germany over a period of 30 years, however, was associated with a reduced number of hip fractures in the very old. 144 A number of studies 89, [136] [137] [138] 145 have been performed in people with osteoporosis using 20 to about 26 mg of fluorine per day with additional calcium supplementation of 400 and 1000 mg. After study periods ranging from 12 to 48 months, increases in lumbar spine BMD of 10 to 24% were found. In late postmenopausal women with 146 or without 147 osteoporosis, supplementation with 1000 mg of calcium in combination with 11.2 and 13.5 mg of fluorine, respectively, increased BMD of the lumbar spine with 12.6 and 17%, respectively, during study periods of 3 years. Three of the previously mentioned studies with a duration of 36 or 48 months also reported increases in BMD of the femoral neck, 138, 146 Ward's triangle and greater trochanter, 146 and total hip. 145 Only in the low-dose study 146 were the increases in BMD of the hip significantly different from calcium supplementation alone. Furthermore, all three studies showed a decrease in spinal fracture rate. It has been suggested that the loss of cancelous bone microarchitecture before treatment might explain the low or absence of reduction in fracture risk in other studies. 89 No differences were found between continuous and intermittent administration of the same total amount of fluorine. Biopsies indicate that the incidence of osteomalacia was related to fluoride dosage (26 and 34 mg of fluorine), but could, at least in part, be overcome by additional vitamin D supplementation. 137 The use of slow release fluorine may have advantages, as it avoids a sharp increase in serum fluorine that may result in unwanted side effects. 1 Treatment of postmenopausal women with high doses of fluorine (about 25 mg per day) may strongly increase BMD, especially of the lumbar spine, but may also increase brittleness of bone. Lower doses of fluoride (about 10 mg per day) showed a reduction of spinal fracture incidence. An adequate intake of calcium and vitamin D is necessary.
VII. BORON
Boron may have a function in the maintenance of bone health, especially in the case of deficiencies of vitamin D, magnesium, and potassium. 8, 148 Other positive activities may be present in the field of heart disease and stroke, glucoserelated disorders, brain alertness, and aging. 149 When there is no nutritional or metabolic stress, the need for boron seems to be low. 150 A level of about 1 mg per day has been suggested. Intakes of 3 to 4 g of boron for adults and 1 g for infants are thought to be toxic. 149 Tissues affected by boron deprivation are the skeleton, kidney, and brain. 151 Good sources of boron are fruits, 152 vegetables, 149 nuts, 153 and eggs. Particularly rich sources are wine, raisins, dried parsley, and caviar (with boric acid as preservative). 149 Cow's milk may contain boron in a wide range of 20 to 1000 µg/L, which is considered to reflect the amount in the diet. 152, 154 Daily average intakes were calculated to range from 0.3 to 41 mg per day, 149 but perhaps a more realistic reported range is 0.5 to 3.1 mg of boron per day. 155, 156 The wide range in estimated intakes can be explained by differences in methods of analysis, and a high variability in the natural distribution of boron. 149
A. Intestinal Absorption and Action on Bone and Bone Tissue
Boron is rapidly and efficiently absorbed. 155 Several animal studies (rats, mice, and pigs) have shown that boron supplementation (3 to 12 mg/kg diet or per kg body weight) influenced metabolism and functional properties of bone in combination with calcium-and magnesium-deficient diets. 157, 158 Different effects were seen on the femur and vertebrae, being often positive for the latter (increased compression load) but negative for the former (thinner femur wall, diminished bone, and osteoid mass). A high boron intake (350 mg/L of drinking water) reduced osteoblastic activity in rats. 158 Boron supplementation (3 mg/day) increased serum concentrations of 17βestradiol and testosterone in postmenopausal women 159 possibly by changing the rate or pathway for the catabolism and excretion of these hormones. 8 This effect was especially present in women with a low magnesium status. 159 Some findings suggest that boron enhances 149 the formation of active or hydroxylated forms of some specific steroid or steroid-related hormones (e.g., the hydroxylated form of vitamin D). 154 Furthermore, boron may have a regulatory role in maintaining proper cell membrane function (e.g., transmembrane signaling) or stability. 151 It seems that boron supplementation leads to an accumulation of boron in bone but not in soft tissue, whereas a high percentage of the absorbed boron is rapidly excreted in urine. 8, 152 
B. Effects of Boron Supplementation
Boron has been reported to have an antiarthritic effect at intakes of 3 to 10 mg per day, possibly through stimulation of the synthesis of corticosteroids. 149, 160 A protective role for boron in postmenopausal bone loss is suggested. Nielsen et al. 159 studied 12 healthy postmenopausal women in a metabolic unit who received a supplement of 3 mg of boron after a 17-week period of low-boron diet (0.25 mg). Following boron supplementation, a decreased calcium (0.13 to 0.09 g/d) and magnesium (0.11 to 0.06 g/d) excretion was found in 24-h urine collections, within 8 days. Furthermore, these women showed a significant increase in plasma estradiol (21.1 to 41.4 pg/ml) and testosterone (0.31 to 0.83 ng/ml) concentrations. The effects were smaller in seven women consuming 315 mg magnesium per day, compared with five women taking 115 mg magnesium per day. In a follow-up study with four postmenopausal women, on a low magnesium diet, effects of boron supplementation on parameters of calcium metabolism were comparable with effects seen on estrogen therapy (lower serum calcitonin and increased plasma ionized calcium). 148 Based on these findings, the authors suggest that boron may aid in the prevention of agerelated bone loss, as estrogen therapy is known to be beneficial for bone. 148 However, the boron effects were not confirmed by Beattie and Peace. 8 In their study, six women, in a metabolic unit, received a boron supplement (3 mg/day) in addition to a low-boron diet. Total daily boron intake was 3.33 mg/day. In 24-h urine collections, excretion of calcium and magnesium increased during the boron depletion period but was not restored during boron supplementation. No effects were found on the urinary excretion of deoxypyridinoline, or on plasma estradiol and testosterone concentrations. Compared with the former studies, participants in the study of Beattie and Peace had lower baseline serum estradiol concentrations (range 2 to11 pg/ ml), a daily intake of about 300 mg magnesium (possibly even higher), and a shorter boron depletion period (3 vs. 17 weeks). A period of more than 21 days may be necessary to induce detectable effects of boron depletion. 161 In healthy male subjects, however, plasma estradiol concentrations increased significantly after daily supplementation with 10 mg boron for 4 weeks, without a preceding boron depletion period. 162 The habitual boron intake ranged from 0.35 to 3.53 mg/day. The higher intake of magnesium in the study of Beattie and Peace may have blunted the effect of boron especially 163 and may explain the absence of a reducing effect on calcium excretion. A daily intake of about 300 mg of magnesium combined with boron supplementation was found to increase urinary calcium loss in postmenopausal women at a later date. 153 Clinical observations suggest that boron supplements accelerate the healing of broken bones. 160 In postmenopausal women, additional boron (about 3 mg per day) may have a positive influence on bone through stimulation of gonadal hormones synthesis. However, evidence is weak, and positive effects are especially seen in combination with deficiencies of vitamin D and magnesium.
VIII. VITAMIN K
Compounds with vitamin K activity contain the 2-methyl-1,4-napthoquinone nucleus with a lipophilic side chain at position 3. 155 Three types of vitamin K are known, vitamin K 1 or phylloquinone, vitamin K 2 series or menaquinones (called MK-4 up to MK-13), and menadione (formerly vitamin K 3 ). 19, 164 The latter may be toxic, as it can combine with sulfydryl groups in membranes. 155 Vitamins K 1 and K 2 have a much lower toxicity. 56 Vitamin K 1 is present in dark, leafy green vegetables (40 to 50% of total intake 165 ), fruit, and vegetable oils. 166 Amounts in dairy products and grains may vary from 2 to 70 µg/kg. 164 Vitamin K 2 , estimated to contribute 10 to 30% to daily vitamin K requirement, 155 is found in fermented dairy and soy products and is synthesized by the intestinal microflora. 86, 165 Moderate amounts are found in fish, meat, liver, and eggs. 86, 164 The dietary intake of vitamin K, as well as the circulating levels (expressed as a ratio to triglyceride), decrease with age. 164, 165 It is of interest to know that vitamin K might be an important inhibitor of the aging of the nervous system. 167 High losses (40 to 60% in feces) and low body stores (50 to 100 µg) emphasize the need for a daily supply of vitamin K. 155, 166 Based on markers of bone formation and on BMD, it is suggested that vitamin K intakes should be much higher than the current recommendations (80 µg for men and 65 µg for women, US RDA 1989). 168 In The Netherlands, the daily intake of vitamin K 1 , by subjects 55 to 70 years of age, was found to be about 250 µg per day. 169
A. Intestinal Absorption and Action on Bone
Intestinal absorption of vitamin K 1 along with dietary fat occurs with an efficiency of 40 to 80%. 170 Supplemented vitamin K has a high absorbability. 171 Vitamin K 1 absorption from the natural food matrix is low, absorption from green vegetables was found to be 5 to 15%. 172 Vitamin K 2 derived from the intestinal microflora possibly is absorbed in the terminal ileum along with the reabsorption of bile salts. Long MKs are poorly absorbed. 60, 166 After absorption, vitamin K 1 is transported in chylomicrons to target tissues and the liver. 164 Chylomicrons (and thus vitamin K) are cleared by the liver and bone marrow. Dependent on the genetic variant of the apoE, this clearance rate is higher or lower (apoE4>apoE3>apoE2). 173, 174 A part of the vitamin K 1 might be delivered to extrahepatic tissues via low-density lipoprotein. 174 Liver stores of vitamin K, for about 90% consisting of MK-7 to MK-13, are relatively small. 166, 175 The dominant form in bone is vitamin K 1 . 173 Vitamin K is an essential co-factor in posttranslational carboxylation, transforming specific glutamate residues (Glu) into γ-carboxyglutamic acid (Gla). Gla residues increase the affinity of proteins for calcium. 176 Deficiency or antagonism of vitamin K (e.g., by coumarin derivatives, 175 or vitamin A and E in pharmacological doses 56, 155 ) results in undercarboxylation of the specific proteins. Matrix Gla protein, protein S, nephrocalcin, and osteocalcin are vitamin K-dependent proteins involved in bone metabolism. 177 Matrix Gla protein, synthesized in osteoblasts and most soft tissues, is stimulated by calcitriol, 164, 177 and does not react with hydroxyapatite. 155 This protein appears earlier than osteocalcin, possibly preventing calcification of arteries and cartilage. 177, 178 Protein S is produced by osteoblasts, hepatocytes, megakaryocytes, and endothelial cells. Based on reported osteopenia and vertebral body compression fractures in the case of protein S deficiency, a role in bone metabolism is suggested. 164, 179 Nephrocalcin probably was involved in a reduction of urinary calcium loss in a group of 'fast calcium losing' postmenopausal women. No effect was seen in 'normal' or 'slow' losers. 179 Osteocalcin is the most well-known vitamin K-dependent protein in bone metabolism, synthesized by osteoblasts and osteocytes (particularly newly embedded osteocytes). 176 Carboxylated osteocalcin with three Gla residues has a high affinity for hydroxyapatite, and as a consequence inhibits hydroxyapatite formation. 155 In this way, carboxylated osteocalcin seems to be a regulator of bone formation, possibly by stimulating a proper, slow mineral maturation, and by preventing an excessive mineralization. 176, 180, 181 Plasma carboxylated osteocalcin concentrations arise from new cellular synthesis, rather than from resorption or release from bone matrix. That is why osteocalcin is used as a marker of osteoblast activity. 176 The C-terminal domain of osteocalcin, however, has chemotactic properties for osteoclast progenitor cells (monocytes), which suggests also a role in bone resorption. 77, 175, 176 In osteocalcin-free mutant mice, bone resorption, or osteoclast function, was not altered. 180 However, in combination with estrogen deficiency, osteocalcin-free mice developed more severe osteoporosis than normal ovariectomized wild-type mice. 60, 180 In human, the concentration of undercarboxylated osteocalcin in serum, or its ratio with carboxylated osteocalcin, seems to be a sensitive indicator for bone pathology 182, 183 and a predictor of fracture risk. 177, 184 In postmenopausal women, 1 to 10 years past menopause, undercarboxylated osteocalcin was correlated with lower BMD of Ward's triangle and femoral neck in particular. 185 From a prospective study in women, an inverse association between dietary vitamin K and the risk of hip fractures was observed. 186 The percentage of carboxylated osteocalcin from total osteocalcin was found to range from 70 to 80% in young, healthy adults. In postmenopausal women this percentage was decreased to 60% or less. 178, 187 Other reported vitamin K antiosteoporotic activities are the inhibition of interleukin-6 by vitamin K 1 , K 2 , and menadione in vitro, 188 and inhibition of osteoclast formation and stimulation of their apoptosis specifically by MK-4. 60, 164 
B. Effects of Vitamin K Supplementation
In postmenopausal women with fractures of the distal radius, the percentage of carboxylated osteocalcin rose from 56.1 to 74.8%, after a daily intake of 1 mg of vitamin K 1 for only 2 weeks. 189 In another group of postmenopausal women, carboxylated osteocalcin was correlated with alkaline bone phosphatase, whereas undercarboxylated osteocalcin was correlated with urinary calcium excretion after 3 months of treatment with 1 mg of vitamin K per day. 183 Treatment of postmenopausal women, who were high calcium losers, with 1 mg of vitamin K 1 per day for 2 weeks, reduced urinary excretion of calcium and hydroxyproline by 10 to 50%. 187 In young, healthy subjects (20 to 40 years of age) and in older subjects (60 to 80 years of age), an increase in the daily intake of vitamin K during 5 days from 100 to 420 µg, reduced the undercarboxylated fraction of osteocalcin by about 40%. 190, 191 MK-4, synthesized from menadione or K 1 , 60 in large doses (45 mg/d) was found to have a significant therapeutic effect on involutional osteoporosis. 192 The same dose of MK-4 (45 mg/day) was effective in 54 vitamin D-and vitamin K-deficient stroke patients. After 12 months of treatment, their BMD of the second metacarpal on hemiplegic sides increased with 4.3% ± 9.9%, whereas the loss in BMD on the intact side was smaller compared with the untreated group. 193 The role of vitamin K in bone is not yet resolved, but a bone health-stimulating effect is suggested. The percent carboxylated osteocalcin from total osteocalcin may be used as a sensitive marker for vitamin K status.
IX. VITAMIN C
Vitamin C (ascorbic acid) is a simple sugar and powerful reducing agent synthesized from glucose in many plant and animal tissues, but not in humans. Enzyme reactions that require vitamin C include those involved in the synthesis of hydroxyproline and hydroxylysine, and the amidation of calcitonin. 19, 103 Of the fresh fruit and juices, black currant, guavas, Hawthorn berries, acerola, and rose hips are particularly rich in vitamin C. Other important sources are leafy, green vegetables. 19 The daily recommended amount of vitamin C is 60 mg for those older than 50 years of age; 94 however, this will probably increase to levels of 100 to 200 mg/day. Although intakes higher than 1000 mg of ascorbic acid do not seem to cause toxic symptoms, routine use of such large doses is not recommended. 103
A. Action on Bone Metabolism
Vitamin C is well absorbed, >80% at low doses (60 mg), by passive and active transport mechanisms particularly in the small intestine. The body pool has been calculated to be greater than 1400 mg in healthy male adults, with a turnover rate of 45 to 60 mg/day. 56 Osteoblasts contain a specific saturable, stereo-selective (low uptake of D-isoascorbic acid) transport system for vitamin C, 194 which is probably Na + gradient dependent. 195 The maximum capacity of the Na + -dependent transporter is within the range of normal serum levels of vitamin C of about 10 to 100 µM/L. 196 These levels can be achieved with intakes of 40 to 1000 mg of vitamin C per day. 155 Therefore, higher dietary intakes would not have much effect on uptake into tissues that produce collagen. 196 It seems that vitamin C increases hydroxylation (by prolyl-and lysylhydroxylases 19 ) of procollagen approximately fivefold. 194 This is an important stimulus for an increased translation and transcription of pro-collagen mRNA. Furthermore, vitamin C stimulates osteoblasts to produce osteocalcin and alkaline phosphatase, and to lay down bone matrix. 194, 196 Bacterial lipopolysaccharides, which activate the antimicrobial complement system, have been reported to inhibit vitamin C transport into the osteoblast. This inhibition by complement may, in part, explain the defects in bone repair associated with inflammatory bone diseases such as periodontitis. 195 Urinary excretion of vitamin C, as free ascorbic acid or as oxalate, occurs when the plasma concentration exceeds 70 µM/L. A high excretion of oxalate may cause the development of oxalate stones. 19
B. Vitamin C and BMD
In healthy premenopausal women the intake of vitamin C (126 ± 96 mg/day, range 16 to 1164 mg) has been positively correlated with BMD of the lumbar spine, the greatest effects were seen with moderate (second and third quartiles of) vitamin C intakes. 6 In postmenopausal Mexican-American and Caucasian-American women, a positive association was found between dietary vitamin C and femoral neck BMD. 197, 198 In the Caucasian women, the association of vitamin C with BMD was stronger when diets were higher in calcium (>500 mg/day). 198 This agrees with other studies that link vitamin C with a lower risk for hip fracture. 197 An association between dietary vitamin C (113 mg/day) and BMD of the hip was not found in another U.S. study 199 of postmenopausal women. However, long-term use of vitamin C supplements (mean total intake of 407 mg of vitamin C per day) was associated in this group with higher BMD of the hip, especially in those participants who never used estro-gen preparations and only in women 55 to 64 years of age.
These studies suggest a positive role of vitamin C in the prevention of postmenopausal bone loss in moderate amounts, 6 but that are higher than the amounts currently recommended. 199
X. DISCUSSION
A high peak bone mass after adolescence provides a profitable starting point at the moment bone mass is lost because of aging and menopause. Following menopause, an adequate intake of a number of nutrients will delay or prevent natural bone loss ( Table 2 ). The basic element is calcium. Small differences in absorption between several calcium sources do not play an important role. The problem of a lower gastric acid secretion in older women can be overcome by supplementing with liquid calcium citrate, 200 but also by supplying calcium supplements together with the meal. 201 Problems with the inhibition of other ingredients in the meal are, except for iron, not to be expected. Frequently ingesting smaller amounts of calcium are preferred over a single dosage because the efficiency of absorption increases. The effects of calcium supplementation in early postmenopausal women is moderate but nevertheless useful because marginal or low calcium intakes are prevented, and estrogen and calcitonin therapies are improved. 41 In late postmenopausal women and in the elderly, calcium supplementation to a total daily calcium intake of at least 1500 mg seems to increase BMD of the spine in particular, and can reduce the number of fractures. 42, 43, 202 Fracture reduction is also suggested from vitamin D studies with older women, 86, 87 especially in combination with a sufficient calcium intake. 32 Prevention strategies and long-term use indicate that effective additional amounts are in the range of 400 to 800 IU of vitamin D per day. Appropriate intakes should lead to serum calcidiol levels of about 100 nmol/L. 59 Early postmenopausal women are not very sensitive to vitamin D therapy. A declined setpoint for bone mass as a result of estrogen deficiency causes an increased loss of bone, as a consequence sufficient serum calcium levels, and a decreased need for calcitriol synthesis. 1, 38 Only treatment with ready-to-use vitamin D metabolites seems to be effective at this stage of life. The role of magnesium in bone health seems to be underestimated, because five suggested functions of magnesium stimulate bone strength, bone preservation, and possible bone formation. The effects of magnesium on blood pH are highest about 4 hours after intake, which makes extra magnesium in the evening most effective because ECF pH is lowest at night. 203 Another beneficial effect of magnesium is the inhibition of soft tissue calcification, 95 which is suggested to be positive for the cardiovascular system, especially in cases of high-calcium diets. 155 Strontium might be a very interesting element with anabolic effects on bone through stimulation of osteoblasts and inhibition of osteoclasts. The effective amounts, however, are not clear. Although high amounts (e.g., 170 mg per day) showed positive effects on BMD, 204 incorporation of strontium into hydroxyapatite crystals, which is a long-term effect, may lead to a reduced bending strength, a higher solubility, and probably a higher rate of remodeling. In contrast, when strontium adheres to existing hydroxyapatite, which is a short-term effect, bone strength increases, and solubility reduces. 123, 124 The intake of strontium therefore should be low enough to minimize incorporation into newly formed crystals, but high enough to have an effect on the surface of existing crystals. That is why in preventive strategies, for the time being, additional amounts of strontium close to the suggested daily intakes of 1 to 3 mg might be preferable over therapeutic doses of 170 mg.
Fluorine intakes, varying from about 14 to 30 mg per day, are able to increase BMD of the axial skeleton considerably, but effects on fracture reduction are marginal. The effects on BMD of the hip are much smaller. Due to fluorine incorporation into hydroxyapatite crystals, bending strength might even decrease. 1 The incorporation of fluorine also decreases solubility and by that remodeling. In time, fluoride concentrations in bone may reach toxic levels. On the one hand, it has been shown in vitro 1 that high concentrations of fluorine are necessary for the stimulation of os-teoblasts, probably >26 mg of fluorine per day. 138 On the other hand, especially low intakes of fluorine were associated with a decreased number of hip fractures in elderly 144 and late postmenopausal women. 146 This, and because the anion is bone seeking and has a long residence time, are in favor of a chronic supply of low amounts of fluoride (e.g., by a regular consumption of tea and other fluoride-rich food ingredients). In all cases of increased fluoride consumption, sufficient intakes of calcium and vitamin D are necessary to support a proper mineralization. 1, 132 The role of boron in bone metabolism is especially pronounced in the case of magnesium deficiency. The best effects are seen in patients with arthritis. For these people, the suggested boron requirement of about 1 mg per day 150 seems to be too low. 160 In postmenopausal women, the preservation of estrogens 8 is a positive aspect. The proper dosage of boron, however, is far from clear, 158 but 3 mg of boron per day already suggests positive effects on bone, 149 which is within an achievable dietary range.
Although a number of studies have indicated positive effects of vitamin K on bone health, 179, 184, 205 no established causal relationship between vitamin K deficiency and reduced BMD or increased fracture rate has been found so far. 179 Based on the percentage of carboxylated osteocalcin from total osteocalcin, daily vitamin K intakes should be higher in postmenopausal women than currently recommended. Treatment with additional vitamin K increased carboxylated osteocalcin 189 and increased osteoblast activity. 183 This fits within the well-known role of osteocalcin as a marker of bone formation. However, it has been suggested that osteocalcin especially plays a role in the 'after bone formation' period in the coupling of formation and resorption. 180 This might also explain why osteocalcin has been found to increase in a late stage of fluoride therapy. 136 Perhaps other vitamin K-dependent proteins, matrix Gla protein and nephrocalcin in particular, deserve more attention.
Vitamin C seems to play a role in bone formation by stimulating osteoblasts (synthesis of alkaline phosphatase and procollagen) and possibly by inhibition of osteoclasts through stimulating the amidation of calcitonin. This is in line with reported positive associations between vita-min C intake and BMD of lumbar spine and hip. 6, 197, 199 Based on the capacity of osteoblasts to take up vitamin C, dietary amounts higher than 1000 mg/day are not necessary, but amounts considerably higher than the current recommendations might be beneficial.
Based on the above discussion, it can be concluded that the aforementioned nutrients play a positive role in the delay of natural bone loss ( Table 2) , although for boron this might only be true when magnesium is deficient. It also can be stated that for the aforementioned nutrients, a considerable increase (dependent on the component 30 to 100%) of recommended amounts, 94 adequate intakes 13 or doubling of the estimated normal intakes, or less than that already may be very beneficial. Pharmacological amounts, although therapeutically effective, do not seem to be necessary in preventive strategies. Complete foods or supplements are preferred over the supplementation of single nutrients because of the complexity of natural bone loss, the diversity in dietary habitats, and nutrient-nutrient interactions. Prevention or treatment with nutrients is most effective in late postmenopausal women and elderly. Despite only moderate effects in the early postmenopausal stage, additional supplementation may at least overcome the extra bone loss as a result of undernutrition.
